Wells Fargo & Company Kezar Life Sciences, Inc. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KZR
# of Institutions
61Shares Held
38.4MCall Options Held
13.8KPut Options Held
600-
Suvretta Capital Management, LLC New York, NY7.17MShares$53.5 Million0.22% of portfolio
-
Avidity Partners Management LP Dallas, TX5.03MShares$37.5 Million0.24% of portfolio
-
Tang Capital Management LLC San Diego, CA3.64MShares$27.2 Million0.24% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.74MShares$20.5 Million0.0% of portfolio
-
Affinity Asset Advisors, LLC New York, NY2.51MShares$18.8 Million0.33% of portfolio
About Kezar Life Sciences, Inc.
- Ticker KZR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,369,504
- Market Cap $511M
- Description
- Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...